A Phase II, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Assess The Oral Corticosteroid-Sparing Effect Of Lebrikizumab In Patients With Severe Corticosteroid-Dependent Asthma

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Assess The Oral Corticosteroid-Sparing Effect Of Lebrikizumab In Patients With Severe Corticosteroid-Dependent Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Lebrikizumab (Primary) ; Corticosteroids
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms VOCALS
  • Sponsors Roche
  • Most Recent Events

    • 19 May 2017 Status changed from discontinued to completed.
    • 11 May 2017 This trial has been completed in the Netherlands.
    • 25 Apr 2017 This trial has been completed in Poland (End date:2016-12-21) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top